Rhabdomyosarcoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions.
Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy, and radiation therapy.
The Rhabdomyosarcoma drugs in development market research report provide comprehensive information on the therapeutics under development for Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Rhabdomyosarcoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 74 molecules, with 66 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Rhabdomyosarcoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Rhabdomyosarcoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Rhabdomyosarcoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAbbisko Therapeutics Co Ltd
AbbVie Inc
Actuate Therapeutics Inc
Aptadel Therapeutics SL
AstraZeneca Plc
Bayer AG
Biogenera SpA
Bristol-Myers Squibb Co
Cellectar Biosciences Inc
Children's National Research Institute
Edison Oncology Holding Corp
Eisai Co Ltd
Evgen Pharma Plc
Exelixis Inc
F. Hoffmann-La Roche Ltd
GAiA BioMedicine Inc
Gate2Brain SL
Hutchison MediPharma Ltd
Immatics NV
Immix BioPharma Inc
Immugenia Inc
Iproteos SL
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Kronos Bio Inc
Lantern Pharma Inc
Lirum Therapeutics Inc
MacroGenics Inc
Mana Therapeutics Inc
Manhattan Biosolutions Inc
Medosome Biotec LLC
Mirati Therapeutics Inc
NanoRED Biotechnology
Nationwide Children's Hospital
neoX Biotech (HK) Ltd
North Carolina Central University
Novartis AG
NovoMedix LLC
Ohara Pharmaceutical Co Ltd
Ohio State University
Oncoheroes Biosciences Inc
Oncolys BioPharma Inc
Onconova Therapeutics Inc
Orgenesis Inc
Orphelia Pharma SAS
Peel Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Philogen SpA
Provectus Biopharmaceuticals Inc
SELLAS Life Sciences Group Inc
Shanghai Junshi Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shepherd Therapeutics Inc
Shionogi & Co Ltd
Sorrento Therapeutics Inc
Taiwan Liposome Co Ltd
Talus Bioscience Inc
Tyra Biosciences Inc
U.S. National Institutes of Health
University Hospital Tubingen
University of California San Francisco
University of South Australia
Veana Therapeutics LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Rhabdomyosarcoma reports